Biogen Idec, Inc. (Massachusetts) Increases Revenue 18% to $1.4 Billion in the Second Quarter

July 24, 2012 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

WESTON, Mass.--(BUSINESS WIRE) Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its second quarter 2012 results.

Twitter
LinkedIn
Facebook
Email
Print

Earnings

Biogen